PMID- 33919732
OWN - NLM
STAT- MEDLINE
DCOM- 20211020
LR  - 20211204
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 10
IP  - 4
DP  - 2021 Apr 14
TI  - New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells 
      (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, 
      and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
LID - 10.3390/cells10040893 [doi]
LID - 893
AB  - Cancer cells "hijack" host immune cells to promote growth, survival, and 
      metastasis. The immune microenvironment of high-grade gliomas (HGG) is a complex 
      and heterogeneous system, consisting of diverse cell types such as microglia, 
      bone marrow-derived macrophages (BMDMs), myeloid-derived suppressor cells 
      (MDSCs), dendritic cells, natural killer (NK) cells, and T-cells. Of these, MDSCs 
      are one of the major tumor-infiltrating immune cells and are correlated not only 
      with overall worse prognosis but also poor clinical outcomes. Upon entry from the 
      bone marrow into the peripheral blood, spleen, as well as in tumor 
      microenvironment (TME) in HGG patients, MDSCs deploy an array of mechanisms to 
      perform their immune and non-immune suppressive functions. Here, we highlight the 
      origin, function, and characterization of MDSCs and how they are recruited and 
      metabolically reprogrammed in HGG. Furthermore, we discuss the mechanisms by 
      which MDSCs contribute to immunosuppression and resistance to current therapies. 
      Finally, we conclude by summarizing the emerging approaches for targeting MDSCs 
      alone as a monotherapy or in combination with other standard-of-care therapies to 
      improve the current treatment of high-grade glioma patients.
FAU - Lakshmanachetty, Senthilnath
AU  - Lakshmanachetty S
AUID- ORCID: 0000-0002-3760-2772
AD  - Morgan Adams Brain Tumor Research Program, Department of Pediatrics, Division of 
      Hematology/Oncology/Bone Marrow Transplant, University of Colorado Anschutz 
      Medical Campus, Aurora, CO 80045, USA.
FAU - Cruz-Cruz, Joselyn
AU  - Cruz-Cruz J
AUID- ORCID: 0000-0003-2760-3648
AD  - Morgan Adams Brain Tumor Research Program, Department of Pediatrics, Division of 
      Hematology/Oncology/Bone Marrow Transplant, University of Colorado Anschutz 
      Medical Campus, Aurora, CO 80045, USA.
FAU - Hoffmeyer, Eric
AU  - Hoffmeyer E
AD  - Morgan Adams Brain Tumor Research Program, Department of Pediatrics, Division of 
      Hematology/Oncology/Bone Marrow Transplant, University of Colorado Anschutz 
      Medical Campus, Aurora, CO 80045, USA.
FAU - Cole, Allison P
AU  - Cole AP
AD  - Morgan Adams Brain Tumor Research Program, Department of Pediatrics, Division of 
      Hematology/Oncology/Bone Marrow Transplant, University of Colorado Anschutz 
      Medical Campus, Aurora, CO 80045, USA.
FAU - Mitra, Siddhartha S
AU  - Mitra SS
AD  - Morgan Adams Brain Tumor Research Program, Department of Pediatrics, Division of 
      Hematology/Oncology/Bone Marrow Transplant, University of Colorado Anschutz 
      Medical Campus, Aurora, CO 80045, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210414
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
SB  - IM
MH  - Brain Neoplasms/*immunology/*metabolism/pathology
MH  - *Drug Resistance, Neoplasm
MH  - Glioma/*immunology/*metabolism/pathology
MH  - Humans
MH  - *Immunosuppression Therapy
MH  - Myeloid-Derived Suppressor Cells/*immunology/*metabolism/pathology
MH  - Neoplasm Grading
PMC - PMC8070707
OTO - NOTNLM
OT  - MDSCs
OT  - brain tumors
OT  - glioblastoma
OT  - glioma
OT  - high-grade glioma
OT  - immune suppression
OT  - immunotherapy
OT  - metabolic reprogramming
OT  - therapeutic resistance
OT  - therapeutic targeting
OT  - tumor microenvironment
COIS- The authors declare no conflict of interest.
EDAT- 2021/05/01 06:00
MHDA- 2021/10/21 06:00
PMCR- 2021/04/14
CRDT- 2021/04/30 01:13
PHST- 2021/03/31 00:00 [received]
PHST- 2021/04/09 00:00 [revised]
PHST- 2021/04/10 00:00 [accepted]
PHST- 2021/04/30 01:13 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2021/04/14 00:00 [pmc-release]
AID - cells10040893 [pii]
AID - cells-10-00893 [pii]
AID - 10.3390/cells10040893 [doi]
PST - epublish
SO  - Cells. 2021 Apr 14;10(4):893. doi: 10.3390/cells10040893.